Where is infusion work growing?
States ranked by growth in Medicare infusion drug spending from CMS data, the therapies driving it, and what it means for infusion nurses.
On this page (5 sections)
Infusion work is growing fastest in Kansas (up 38%), California (up 33%) and Pennsylvania (up 32%), measured by what Medicare paid doctors and clinics for infusion drugs from 2022 to 2024. Nationally that spending rose from $5.1 billion to $6.0 billion (up 19%). More infusion patients usually means more chairs, more centers and more nursing jobs. See infusion jobs.
Key Takeaways
- Medicare paid doctors and clinics $6.0 billion for infusion drugs in 2024, up 19% since 2022.
- Kansas, California and Pennsylvania grew fastest among states with at least $50 million in 2022.
- The therapies that show up most across states are Denosumab (Prolia), Pembrolizumab (Keytruda), Abatacept (Orencia), Daratumumab (Darzalex Faspro): worth knowing if you are moving into infusion.
- This counts doctors' and clinics' Medicare claims only. Hospital outpatient and home infusion are not included, so treat it as a direction, not a total.
States where infusion is growing fastest
| # | State | Growth 2022 to 2024 | Medicare infusion drugs, 2024 | Top therapy | Open jobs |
|---|---|---|---|---|---|
| 1 | Kansas | up 38% | $118 million | Pembrolizumab (Keytruda) | 15 |
| 2 | California | up 33% | $542 million | Pembrolizumab (Keytruda) | 90 |
| 3 | Pennsylvania | up 32% | $251 million | Denosumab (Prolia) | 37 |
| 4 | Minnesota | up 27% | $87 million | Pembrolizumab (Keytruda) | 17 |
| 5 | Iowa | up 27% | $86 million | Pembrolizumab (Keytruda) | 5 |
| 6 | Texas | up 26% | $504 million | Pembrolizumab (Keytruda) | 73 |
| 7 | Colorado | up 25% | $101 million | Pembrolizumab (Keytruda) | 35 |
| 8 | Arizona | up 24% | $221 million | Pembrolizumab (Keytruda) | 45 |
| 9 | Maryland | up 23% | $237 million | Pembrolizumab (Keytruda) | 22 |
| 10 | Oklahoma | up 23% | $81 million | Abatacept (Orencia) | 20 |
| 11 | Georgia | up 23% | $143 million | Pembrolizumab (Keytruda) | 35 |
| 12 | Ohio | up 22% | $130 million | Pembrolizumab (Keytruda) | 28 |
| 13 | Tennessee | up 20% | $197 million | Pembrolizumab (Keytruda) | 37 |
| 14 | Nevada | up 19% | $73 million | Pembrolizumab (Keytruda) | 11 |
| 15 | Florida | up 18% | $749 million | Pembrolizumab (Keytruda) | 88 |
States with at least $50 million in Medicare infusion drug payments in 2022. Open jobs are on InfusionJobs today.
What does this mean for nurses?
Growth in infusion spending usually comes before new chairs, new centers and new openings. A state near the top of this list is a good place to look for infusion work, and the therapies driving it tell you which skills employers will want: oncology and biologic infusions, IVIG and line care.
Why measure it with Medicare?
Most infusion patients are on Medicare, and CMS publishes what it pays doctors and clinics each year. It is the most complete public measure of infusion demand by state. It misses hospital outpatient departments and home infusion, so the real totals are larger.
Frequently Asked Questions
Where is infusion nursing growing?
By Medicare infusion drug spending, fastest in Kansas, California, Pennsylvania, Minnesota, Iowa from 2022 to 2024.
Which infusion therapies should a nurse know?
The most common across states are Denosumab (Prolia), Pembrolizumab (Keytruda), Abatacept (Orencia), Daratumumab (Darzalex Faspro), Romosozumab (Evenity (2 Syringes)), Certolizumab pegol (Cimzia). Oncology biologics, osteoporosis drugs, rheumatology biologics and IVIG lead.
Where does this data come from?
CMS Medicare Part B claims by doctors and clinics, totaled by state by InfusionJobs. No individual doctors or clinics are named. Hospital outpatient and home infusion claims are not in this file.
Pick a growing state and look at its open jobs, or compare pay in the highest-paying states.
CMS, Medicare Physician & Other Practitioners by Provider and Service, 2022 to 2024 (data.cms.gov). Infusion drugs are drug codes where at least half of Medicare payments go to providers who also bill infusion administration. Skin substitutes and vaccines are left out. Pay figures and job counts come from the job posts on InfusionJobs and update weekly. This describes careers and job duties, not clinical practice: follow your orders, your employer's protocols and the product labeling. About our data.